Skip to content

Absci Corporation ABSI Other intangible assets—net

Other intangible assets—net at other companies

Recursion Pharmaceuticals, Inc. logo
Recursion Pharmaceuticals, Inc.RXRX
$294.07M-12.4%
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
$37.46M-9.1%
ADMA Biologics logo
ADMA BiologicsADMA
$630K+39.4%
Xencor logo
XencorXNCR
$7.6M-43.1%
Precigen logo
PrecigenPGEN
$2.86M-30.8%
BridgeBio Pharma logo
BridgeBio PharmaBBIO

Other financials

Income statement

See full
Revenue$215.0K-81.8%
Operating income-$30.8M-11.2%
Net income-$29.6M-12.3%
EPS (diluted)-$0.19+9.5%

Balance sheet

See full
Cash & equivalents$9.7M-84.9%
Total debt$4.0M-37.2%
Total equity$172.0M-13.5%
Total assets$195.6M-15.9%

Cash flow

See full
Operating cash flow-$26.3M-20.5%
CapEx$30.0K+20.0%
Free cash flow-$26.3M-20.5%

Valuation

See full
Market cap$1.57B+341%
Enterprise value$1.57B+425%
P/S855.5×+782×

Profitability

See full
Operating margin-6,723%-14,525pp
Net margin-6,450.8%-13,699pp
FCF margin-5,365.2%-9,300pp

Returns & leverage

See full
Return on equity-63.9%+28.0pp
Debt / equity0.0×
Current ratio6.6×+0.9×

Where this comes from

Reported directly by Absci Corporation in its filing.

Tagged under the XBRL concept us-gaap:IntangibleAssetsNetExcludingGoodwill.

The official record: Absci Corporation’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Absci Corporation's other intangible assets—net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Absci Corporation's other intangible assets—net?
Absci Corporation (ABSI) reported other intangible assets—net of $40.77M in Q1 2026.
How has Absci Corporation's other intangible assets—net changed year-over-year?
Absci Corporation's other intangible assets—net decreased by 7.4% year-over-year, from $44.04M to $40.77M.
What does other intangible assets—net mean?
This represents the net book value of identifiable non-physical assets such as patents, intellectual property, software licenses, and trademarks, excluding goodwill. These assets are vital for companies relying on proprietary technology and R&D. It captures the value of the company's competitive moat derived from its intellectual property portfolio.